Skip to content
Companies

Galaxy Diagnostics

Digital PCR testing for Bartonella infections

Raised to date

$7.2M

of $16.9M offered across 2 Form D filings

Still open
$9.7M
Investors
55
Last filed
Jun 3, 2026

About

Galaxy Diagnostics, Inc. specializes in advanced testing solutions designed to detect elusive flea- and tick-borne pathogens, specifically *Bartonella* species, which are often missed by standard diagnostic methods. By enhancing clinical detection, the company aims to improve patient outcomes and strengthen the connection between human and animal health.

Galaxy Diagnostics stands out for its proprietary Bartonella Digital ePCR™ Platform, which significantly increases diagnostic sensitivity for difficult-to-detect infections.

Funding

$11.2M, first sold Apr 2025$4.1M sold$7M still openApr 20252026
Now
  • EquityFiled Jun 3, 2026Form D
    $3M/ $5.7M
  • EquityFiled Apr 22, 2025Form D
    $4.1M/ $11.2M

Product

Bartonella Digital ePCR™ Platform

Diagnostics

This platform utilizes droplet digital PCR (ddPCR) alongside the patented Bartonella alphaproteobacteria growth medium (BAPGM™) to effectively enrich samples and directly detect *Bartonella* DNA, leading to enhanced diagnostic sensitivity compared to traditional methods.

  • High sensitivity with direct detection of *Bartonella* DNA
  • Combination of ddPCR and BAPGM™ for effective sample enrichment
  • Applicable for both human and animal samples

Built for

Healthcare Providers, Veterinarians, Researchers

People on file